These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35639541)

  • 21. Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis.
    Zheng Q; Cheng Y; Song C; Feng Z; Xu Z
    Neurol Sci; 2023 Sep; 44(9):2999-3003. PubMed ID: 37243794
    [No Abstract]   [Full Text] [Related]  

  • 22. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    Sansone G; Bonifati DM
    J Neurol; 2022 Aug; 269(8):3965-3981. PubMed ID: 35503373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
    Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
    Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Immunogenicity of Additional SARS-CoV-2 Vaccinations in a Patient With Myasthenia Gravis on Mycophenolate: A Case Report.
    McNeish BL; Colletti RB; Hehir MK
    J Clin Neuromuscul Dis; 2022 Dec; 24(2):113-114. PubMed ID: 36409346
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.
    Li HY; Shao LY; Song M; Hu SM; Yue YX; Li HF
    Front Immunol; 2022; 13():923017. PubMed ID: 35990671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electronic health record derived-impact of COVID-19 on myasthenia gravis.
    Roy B; Kovvuru S; Nalleballe K; Onteddu SR; Nowak RJ
    J Neurol Sci; 2021 Apr; 423():117362. PubMed ID: 33639420
    [No Abstract]   [Full Text] [Related]  

  • 27. COVID19 vaccine in myasthenia gravis patients: safety and possible predictors of disease exacerbation.
    Trinchillo A; Esposito M; Habetswallner F; Tuccillo F; De Martino BM
    Neurol Sci; 2023 Feb; 44(2):447-450. PubMed ID: 36567408
    [No Abstract]   [Full Text] [Related]  

  • 28. Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.
    Lotan I; Hellmann MA; Friedman Y; Stiebel-Kalish H; Steiner I; Wilf-Yarkoni A
    Neuromuscul Disord; 2022 Mar; 32(3):230-235. PubMed ID: 35227552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
    Doron A; Piura Y; Vigiser I; Kolb H; Regev K; Nesher N; Karni A
    J Neurol; 2022 Dec; 269(12):6193-6201. PubMed ID: 35907046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review.
    Sriwastava S; Tandon M; Kataria S; Daimee M; Sultan S
    J Neurol; 2021 Aug; 268(8):2690-2696. PubMed ID: 33047223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cogan's sign in a patient with suspected post-COVID-19 vaccine-associated myasthenia gravis.
    Tavares-Júnior JWL; Sobreira-Neto MA; Braga-Neto P
    Rev Soc Bras Med Trop; 2023; 56():e0007. PubMed ID: 37283341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Case of COVID-19 Vaccine Associated New Diagnosis Myasthenia Gravis.
    Chavez A; Pougnier C
    J Prim Care Community Health; 2021; 12():21501327211051933. PubMed ID: 34709075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis.
    Motobayashi M; Inaba Y; Nishimura T; Kobayashi N; Nakazawa Y; Koike K
    Pediatr Neurol; 2015 Apr; 52(4):404-9. PubMed ID: 25661289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 Vaccine.
    Slavin E; Fitzig J; Neubert C; Garcia-Lopez F; Cuevas-Trisan R
    Am J Phys Med Rehabil; 2022 Dec; 101(12):e176-e179. PubMed ID: 35930797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early-Onset Myasthenia Gravis Following COVID-19 Vaccination.
    Lee MA; Lee C; Park JH; Lee JH
    J Korean Med Sci; 2022 Mar; 37(10):e50. PubMed ID: 35289135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination against COVID-19 does not lead to exacerbation in patients with myasthenia gravis.
    Breiner A; Bourque PR
    Muscle Nerve; 2023 Jan; 67(1):1-2. PubMed ID: 36321578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transient neonatal myasthenia gravis due to a mother with ocular onset of anti-muscle specific kinase myasthenia gravis.
    Lee JY; Min JH; Han SH; Han J
    Neuromuscul Disord; 2017 Jul; 27(7):655-657. PubMed ID: 28495046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
    Tereshko Y; Gigli GL; Pez S; De Pellegrin A; Valente M
    J Neurol; 2023 Feb; 270(2):601-609. PubMed ID: 36352330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myasthenia gravis following human papillomavirus vaccination: a case report.
    Chung JY; Lee SJ; Shin BS; Kang HG
    BMC Neurol; 2018 Dec; 18(1):222. PubMed ID: 30593270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of diagnostic tests in myasthenia gravis.
    Nicholson GA; McLeod JG; Griffiths LR
    Clin Exp Neurol; 1983; 19():45-9. PubMed ID: 6568927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.